A dose-escalation study to assess the efficacy and safety of sildenafil citrate in men with erectile dysfunction

BJU International

Volumn 87, Issue 1, 2001, Pages 75-81

  Meuleman, E ^a   Cuzin, B ^b   Opsomer, R J ^c   Hartmann, U ^d   Bailey, M J ^e   Maytom, M C ^f   Smith, M D ^g   Osterloh, I H ^g  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b EDOUARD HERRIOT HOSPITAL   (France)

^c CLINIQUES UNIVERSITAIRES SAINT LUC   (Belgium)

^d HANNOVER MEDICAL SCHOOL   (Germany)

^e EPSOM GENERAL HOSPITAL   (United Kingdom)

^f PFIZER INC   (United States)

^g PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United Kingdom)

Author keywords

Dose escalation study; Efficacy; Erectile dysfunction; Sildenafil

Indexed keywords

PHOSPHODIESTERASE INHIBITOR; SILDENAFIL;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG INDUCED DISEASE; DRUG SAFETY; DYSPEPSIA; ERECTILE DYSFUNCTION; HEADACHE; HUMAN; MAJOR CLINICAL STUDY; MALE; MALE SEXUAL DYSFUNCTION; MULTICENTER STUDY; PRIORITY JOURNAL; RHINITIS; TREATMENT OUTCOME;

ADMINISTRATION, ORAL; ADULT; AGED; AGED, 80 AND OVER; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; HUMANS; IMPOTENCE; MALE; MIDDLE AGED; PATIENT SATISFACTION; PHOSPHODIESTERASE INHIBITORS; PIPERAZINES; SEXUAL BEHAVIOR; TREATMENT OUTCOME;

EID: 0035156333     PISSN: 14644096     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1464-410X.2001.00998.x     Document Type: Article

References (24)

1. Impotence
2. Clinical Guidelines Panel on Erectile Dysfunction: Summary report on the treatment of organic erectile dysfunction
3. Impotence in diabetes mellitus
4. Neurological disturbances of sexual function with special reference to 529 patients with spinal cord injury
5. Sexual functioning in patients with chronic renal failure
6. The prevalence of diabetic impotence
7. Impotence in medical clinic outpatients
8. Chronic advanced liver disease and impotence: Cause and effect?
9. Impotence
10. The prevalence and perceived aetiology of male sexual problems in a non-clinical sample
11. Factors associated with sexual dysfunction following transurethral resection of the prostate
12. The epidemiology of erectile dysfunction
13. Autoinjection of the corpus cavernosum with a vasoactive drug combination for vasculogenic impotence
14. Intracavernous self-injection with vasoactive intestinal peptide and phentolamine mesylate in the treatment of erectile dysfunction
15. Vasoactive intestinal polypeptide and phentolamine mesylate administered by autoinjector in the treatment of patients with erectile dysfunction resistant to other intracavernosal agents
16. Mechanism of vascular smooth muscle relaxation by organic nitrates, nitrites, nitroprusside and nitric oxide: Evidence for the involvement of S-nitrosothiols as active intermediates
17. Physiology of penile erection
18. Role of nitric oxide in the physiology of erection
19. Modulation of vascular cyclic nucleotide phosphodiesterases by cyclic GMP, role in vasodilatation
20. Sildenafil: An orally active type 5 cyclic GMP-specific phosphodiesterase inhibitor for the treatment of penile erectile dysfunction
21. Sildenafil, a novel effective treatment for male erectile dysfunction
22. Oral sildenafil in the treatment of erectile dysfunction
23. Clinical safety of oral sildenafil citrate (VIAGRA) in the treatment of erectile dysfunction
24. The International Index of Erectile Function (IIEF): A multidimensional scale for assessment of erectile dysfunction